Navigation Links
Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint

ulation and often require lengthy and expensive hospital stays. There is no FDA-approved treatment for PMD.

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing drugs for treating severe psychiatric and neurological diseases. Corcept's lead product, CORLUX, is in Phase 3 clinical trials for treating the psychotic features of PMD. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to reduce the effects of the elevated and abnormal release patterns of cortisol seen in PMD. The company has also initiated a proof-of-concept study to evaluate the ability of CORLUX to mitigate weight gain associated with the use of olanzapine. For more information, please visit www.corcept.com.

Forward-looking Statements

Statements made in this news release – other than statements of historical fact – are forward-looking statements. These include information relating to Corcept’s PMD clinical development program and the timing of the completion of Phase 3 trials. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied here. For example, there can be no assurances on the efficacy, safety, enrollment completion or success of clinical trials; the regulatory process or regulatory approvals; commercial success; in addition, trial timetables may not be accurate. Risk factors are explained in the company's SEC filings, all of which are available from its Web site (www.corcept.com) or from the SEC's Web site (www.sec.gov). The company does not have any intention or duty to update forward-looking statements made in this news release.


CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270





Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today announced ... Logo - ... "Our new corporate identity signifies our transformation into a ... predictive analytics platform for patent claim validity." ... of the proprietary AIA Shield™ platform, the Company commenced a ...
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... THOUSAND OAKS, Calif., Sept. 14 Amgen (Nasdaq: ... Bank of America Merrill Lynch Global Healthcare Conference ... at 9:50 a.m. Greenwich Mean Time.  Amgen executives ... Willard Dere, M.D., senior vice president, International Chief ...
... Sept. 14 Praxis EMR has submitted its application to ... apply for HITECH certification in the country. Under the ARRA ... incentives if they can demonstrate "meaningful use" of a certified ... Department of Health and Human Services to test and certify ...
Cached Medicine Technology:Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference 2Praxis EMR Among First to Apply for HITECH Certification 2
(Date:8/29/2015)... Aliso Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Cut Pro X . Each preset contains 15 seconds of unique footage that users ... presets that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, ...
(Date:8/28/2015)... , ... August 29, 2015 , ... Rio Salado ... learning and the student experience as part of the EDUCAUSE - Next Generation Learning ... . , This is the third Breakthrough Models Incubator hosted by EDUCAUSE ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published ... maker Paul LaRocco has gone through to open a pizzeria in Westchester. Mr. LaRocco ... tends to take several months, but the current process, having already gone on for ...
(Date:8/28/2015)... ... , ... The 6th Annual Survivor in the City, Chicago silent auction ... accolade to its cadre of widespread support—an official letter of support and gratitude from ... medical community and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain ...
(Date:8/28/2015)... Chicago,IL (PRWEB) , ... August 28, 2015 , ... ... Stencils Device Library for documenting and diagramming network and data center assets and ... Manufacturer / Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... the verbal IQ levels of children exposed to the epilepsy drug ... to the drug.// ,The study was conducted in 249 children ... mothers with epilepsy and tests were performed on both the mother ... ,It was seen that 41 children exposed to valproic acid during ...
... condition, often present at birth. It is marked by a ... extreme cases, it can make the hip prone to dislocation.// ... strong independent indicator for the development of osteoarthritis (OA) of ... of the leading causes of disability among the elderly. In ...
... a recent study researchers focused on the use ... their impact on cholesterol and C-reactive protein levels. ... the liver that predicts inflammation in the arteries. ... important key to determining cardiovascular risk.,Researchers focused on ...
... worldwide. Problems with a patient's urethra causes urine ... heavy objects. Austrian researchers say // they are ... cells, which they say makes the treatment especially ... from a patient's arm, culture them for six ...
... disorder caused by abnormal surges in the electrical circuits of ... affect more than 2 million people worldwide. More than half ... medications. // ,Researchers now say that a new study ... compared to drug therapy when treating those with temporal lobe ...
... nearly 30 years worth of data on breast cancer patients ... stages of disease at diagnosis and those who are diagnosed ... the most likely to die from the disease. Black women ... white women, as are those whose tumors are negative for ...
Cached Medicine News:
... Testosterone, (17-Hydroxy-4-androstene-3-one), a C19 steroid, is one ... [1]. In postpubertal males, testosterone is secreted ... small amount derived from peripheral conversion of ... been estimated that over 50% of serum ...
... Thyroid-stimulating hormone (TSH) is a 32 kDa ... the anterior pituitary gland [1]. The structure ... of the pituitary and placental gonadotropins, consisting ... identical between these hormones and a unique ...
... Thyroxine (T4) is the primary active ... the thyroid gland [1]. T4 is synthesized ... iodide trapping by the follicular cells, (ii) ... substrate leading to formation of 3-monoiodotyrosine and ...
... primarily by 5-monodeioination of thyroxine (T4) in ... production occurs at a rate which is ... of T3 from the thyroid gland into ... to 80-100 micrograms/day for T4. In addition, ...
Medicine Products: